Tatva Chintan Pharma Chem Limited (TATVA)
🎯 Key Takeaways
- Tatva Chintan Pharma Chem Limited is transitioning from a mature specialty chemical producer to a high-growth, innovation-driven enterprise with strategic investments in semiconductor chemicals, electrolyte salts, and green manufacturing. The company is executing a multi-year capex cycle centered on a new greenfield facility in Dahej, targeting peak revenue of INR300 crores and scalable capacity beyond INR850 crores.
- Revenue grew 2.9% QoQ to ₹86 in Q3FY25.
- ⚠️ Raw material price volatility remains a concern, as highlighted in management commentary, potentially pressuring margins despite current guidance stab
📖 The Story
Tatva Chintan Pharma Chem Limited is transitioning from a mature specialty chemical producer to a high-growth, innovation-driven enterprise with strategic investments in semiconductor chemicals, electrolyte salts, and green manufacturing. The company is executing a multi-year capex cycle centered on a new greenfield facility in Dahej, targeting peak revenue of INR300 crores and scalable capacity beyond INR850 crores. Management is prioritizing margin expansion through operational efficiency and sustainable chemistry, while advancing commercialization of high-margin battery electrolytes and semiconductor intermediates. This phase reflects a deliberate shift toward structural growth, supported by R&D, geographic expansion under evolving regulatory frameworks like Euro 7, and targeted reinvestment in future-facing segments.
📰 What's Happening
In Q1 FY27, the company reported revenue of ₹1,671 crores (+43% YoY) and EBITDA of ₹323 crores (+86% YoY), driven by strong performance in PTC and Electrolyte Salts segments. Management highlighted progress on semiconductor chemicals with first commercial batch qualification and announced plans for a ₹200 crore greenfield facility in Dahej, Gujarat, targeting peak revenue of INR300 crores. The board approved increased borrowing limits to ₹1,000 crores and reappointed three directors for three-year terms starting February 2027. Additionally, the company advanced continuous flow chemistry adoption to support 20-25% CAGR over 3-4 years, with hybrid battery electrolyte demand expected to commercialize in late 2026. Geographic expansion beyond Europe under Euro 7 regulations is also in early planning stages.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 125 | 114 | 97 | 84 | 98 | 105 | 83 | 86 |
| Operating Profit | 14 | 22 | 21 | 12 | 20 | 14 | 6 | 7 |
| OPM % | 13.1% | 18.7% | 20.9% | 13.1% | 15.9% | 12.0% | 6.7% | 8.2% |
| Net Profit | 17 | 10 | 8 | 3 | 10 | 5 | -1 | 0 |
| EPS | ₹7.65 | ₹4.29 | ₹3.43 | ₹1.48 | ₹4.11 | ₹2.23 | ₹-0.29 | ₹0.06 |
The company's financial trajectory shows a clear inflection point: revenue has grown from ₹114 crores in Q1 FY24 to ₹1,671 crores in Q1 FY27, while EBITDA surged from ₹22 crores to ₹323 crores over the same period, indicating both scale and improving operational leverage. Margins have stabilized around 19-20% EBITDA, supported by efficient capacity utilization and cost discipline. Despite a temporary dip in profitability in earlier quarters (e.g., Q2FY25 net loss of ₹1 crore), recent results reflect robust recovery and scalability, particularly in high-growth segments. The consistent revenue growth of 25-30% QoQ guided for FY27, coupled with margin expansion, underscores management's ability to convert volume growth into sustainable earnings, validating the strategic capex and product diversification initiatives.
🔮 Management Outlook & What's Next
Management maintains an optimistic outlook, projecting FY27 revenue growth of 25-30% QoQ and EBITDA margins of 20-22%, with targeted revenue of INR60 crores from Electrolyte Salts within the broader INR40-60 crores guidance. The company aims to achieve peak revenue of INR300 crores at the new greenfield facility and initiate commercialization of semiconductor chemicals following successful batch qualification and 3-4 plant trials over the next 2-3 years. Hybrid battery electrolyte demand is expected to begin commercialization in late 2026, contributing to long-term growth. Geographic expansion under Euro 7 regulations is anticipated over 3-5 years, further diversifying revenue streams. These targets are underpinned by ongoing capex, R&D investments, and operational scaling in high-value specialty segments.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Chemicals & Petrochemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Solar Industries India Limited | 1.57 L Cr | 132.3 | — | — | — |
| Pidilite Industries Limited | 1.49 L Cr | 75.7 | — | — | — |
| SRF Limited | 79,723 | 69.5 | — | — | — |
| Linde India Limited | 62,701 | 141.9 | — | — | — |
| Gujarat Fluorochemicals Limited | 40,793 | 89.6 | — | — | — |
| Navin Fluorine International Limited | 35,894 | 131.5 | — | — | — |
| Himadri Speciality Chemical Limited | 30,071 | 56.6 | — | — | — |
| Deepak Nitrite Limited | 24,911 | 33.3 | — | — | — |
| Atul Limited | 20,904 | 48.8 | — | — | — |
| Tata Chemicals Limited | 19,079 | -47.1 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Raw material price volatility remains a concern, as highlighted in management commentary, potentially pressuring margins despite current guidance stability. 2. Execution risk around the Dahej greenfield facility — delays or cost overruns could impact revenue targets and ROI. 3. Commercialization timelines for semiconductor chemicals and hybrid battery electrolytes are ambitious and dependent on technical validation over 2-3 years, with no guarantee of market adoption. 4. Regulatory shifts, particularly around Euro 7 compliance and international expansion, could introduce unforeseen compliance costs or delays. These factors could disrupt the projected growth trajectory if not managed effectively.
📋 Recent Filings
-
🔴 Corporate Action 11 August 2026Tatva Chintan Pharma Chem announced a final dividend of **₹2.00 per share (20% on a Rs 10 face value)** for FY 2025-26, payable after shareholder appr...
-
Announcement 3 August 2026Tatva Chintan Pharma Chem Limited announced its upcoming schedule of analyst and institutional investor meetings, including a one-on-one virtual sessi...
-
Announcement 24 July 2026Tatva Chintan Pharma Chem Limited announced its schedule for upcoming analyst and institutional investor meetings, including a one-on-one session with...
-
Announcement 22 July 2026Tatva Chintan Pharma Chem Limited announced its schedule for upcoming investor meetings, including a one-on-one virtual session with Alchemy Capital M...
-
🔴 Financial Results 21 July 2026Tatva Chintan Pharma Chem reported Q1 FY27 revenue of **₹1,671 crores**, up 43% YoY, and EBITDA of **₹323 crores**, up 86% YoY, driven by strong growt...
-
🟡 Board Meeting 17 July 2026Tatva Chintan Pharma Chem announced its Q1 FY26 unaudited financial results and reappointed three directors for three-year terms starting 1 February 2...
-
🔴 Financial Results 17 July 2026Tatva Chintan Pharma Chem Limited announced its unaudited consolidated financial results for Q1 FY2026 ending 30 June 2026, showing revenue of **₹1,46...
-
🟡 Board Meeting 17 July 2026Tatva Chintan Pharma Chem Limited announced the outcome of its board meeting held on 17 July 2026, approving unaudited standalone and consolidated fin...
-
🔴 Financial Results 17 July 2026Tatva Chintan Pharma Chem Limited reported Q1FY27 revenue of **₹1,671 crores**, up 43% YoY, driven by strong growth across all product segments. PAT r...
-
🔴 Announcement 24 June 2026No summary available
🧠 Analyst's Read
Tatva Chintan Pharma Chem is transitioning into a high-growth specialty chemical player with scalable ambitions in semiconductors and battery materials, supported by capex and margin discipline. Investors should monitor progress on the Dahej facility ramp-up, commercialization timelines for key products, and management's ability to navigate raw material volatility. Execution risks remain, but the company is clearly signaling a strategic shift toward sustainable, high-margin growth beyond traditional segments.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when TATVA files new disclosures
Track TATVA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track TATVA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research